- Ilant sells obesity and cardiometabolic care to employers and health plans, then serves their members nationwide.
- Its software finds high-risk people and helps clinicians match them to behavioral care, medication, surgery or a combination.
- The company has raised more than $22 million and says its model can produce clinical gains and lower total costs.
- The useful lesson: separate finding the patient, choosing the treatment and supporting adherence. They are different jobs.
The first system to fail Elina Onitskansky was the one she already knew from the inside. She had worked at McKinsey and held a senior strategy role at the insurer Molina Healthcare. She understood care pathways, cost curves and the immaculate diagrams that make medicine appear orderly. Yet when she needed treatment for obesity, clinicians did not direct her to medical options. She referred herself for a bariatric procedure and found an endocrinologist who specialized in obesity medicine.
There is a special kind of absurdity in a healthcare executive becoming her own referral network. It also gave Onitskansky a sharper diagnosis than any pitch deck could: obesity care did not lack treatments. It lacked a reliable way to get a person to the right one, without judgment, and then keep supporting them after the appointment.
She founded Ilant Health in 2022. The name comes from a word meaning trees - an image of growth, but also of branching paths. That metaphor does real work here. Ilant is built on the proposition that the correct route might be intensive behavioral therapy, nutrition support, an older anti-obesity medicine, a GLP-1, metabolic surgery, or several of those over time. A single front door should not imply a single destination.
The switchboard, not the syringe
Most weight-care companies are easy to describe because their object is obvious: an app, a coach, a prescription. Ilant is closer to a switchboard. Employers and health plans hand it a population. Its Ilant Rapid Returns engine uses claims and other data to identify people at elevated risk who might benefit from care. Its Ilant Metabolism Matters system gives clinicians decision support based on medical, behavioral and individual factors. The care team then delivers the work: obesity-medicine physicians, behavioral-health specialists, dietitians and peer navigators, connected through an app.
The Ilant routing logic
That order matters. A prescription-first service begins with a person who has already arrived and often with a product they already expect. Ilant begins one level up, with the buyer's risk pool. The customer is the benefits leader or health-plan executive trying to answer two questions at once: who needs help, and what will happen to the cost trend if we provide it?
“The obesity crisis isn't a GLP-1 cost or access problem - it's a treatment matching and clinical support problem.”Elina Onitskansky, founder and CEO
A buyer with two scoreboards
The tension in employer-sponsored obesity care is almost comically tidy. Decline broad medication coverage and people lose access to effective treatment. Open the gate without clinical targeting or follow-up and pharmacy spending can rise faster than demonstrated health gains. Ilant enters between those positions. Its direct relationships with Eli Lilly and Novo Nordisk are intended to make medication pricing more predictable, while its clinical model decides when medication belongs in a wider plan.
This is what “value-based” means in Ilant's sales language: the company wants to be evaluated not by the number of video visits or prescriptions, but by weight, biometrics and total cost. SEIU 775 Benefits Group is one named customer. Ilant says that among engaged members in that caregiver population, six-month results included 10 percent weight loss and more than 50 percent improvement in biometrics. Galway Holdings has also offered the program to its own employees and employer clients.
Company-reported portfolio figures. Results for any member or customer will vary.
The caveat is not ornamental. A young care company can publish persuasive cases before it has the independent, long-duration evidence needed to settle the argument. Weight change is visible quickly; avoided cardiac events are not. A one-year return depends on which costs are counted, what the comparison group looks like and whether members remain engaged. Ilant's commercial future rests on turning early cases into repeatable evidence.
What $22 million is buying
The company started with a $3 million seed round, extended that round to $5.5 million in 2024, and raised $15 million in June 2026. The capital is funding something more laborious than a medication marketplace. Nationwide clinical operations require licensed providers, navigation, data connections, measurement and relationships with plans, employers, labs, health-information networks and drugmakers.
That also explains Ilant's competitive position. Form Health, Calibrate, Vida Health, Omada, Virta, FlyteHealth and Wondr all occupy parts of the employer cardiometabolic market. Ilant's distinction is not that it alone combines people and software. It is the particular sequence: population risk first, treatment matching second, multidisciplinary care third, financial outcomes throughout. The company is trying to be the accountable layer across the choices rather than one more choice in the benefits catalogue.
The first failure was a handoff
Onitskansky has described the shame of not having lost weight “on my own,” even after treatment changed her life. The phrase exposes the cultural problem beneath the operational one. A system can technically cover obesity care and still make a patient feel that using it is evidence of weakness. Ilant's peer navigators and nonjudgmental tone are therefore not soft additions to the clinical engine. They are mechanisms for reducing abandonment.
Her mind changed because treatment quieted a struggle she had been taught to interpret as personal failure. She began running - first a 5K, then a 10K - and eventually began talking publicly about the medical support she had once concealed. Ilant's founding bet is that people do better when care replaces the moral lecture.
The part worth copying
- Find risk before waiting for a motivated consumer to raise a hand.
- Keep treatment selection separate from enthusiasm for any one treatment.
- Measure clinical change and financial change on the same scoreboard.
- Design human follow-up as infrastructure, not encouragement sprinkled on top.
This playbook depends on conditions that are easy to miss: usable population data, benefit coverage, a willing employer or plan, enough licensed clinicians, and members who consent to sustained engagement. Without those, precision becomes a handsome word attached to partial information. Direct drug pricing may lower one barrier without fixing the rest. And a risk model, however clever, cannot help a person the system cannot reach.
Still, Ilant has chosen the right difficulty. The GLP-1 boom made obesity treatment newly visible, but visibility is not coordination. Someone still has to decide who needs what, explain the tradeoffs, watch what happens and change course. The company built from one missing referral is trying to make that sequence feel ordinary. In American healthcare, ordinary coherence is an ambitious product.